Entrada Therapeutics Inc
NASDAQ:TRDA

Watchlist Manager
Entrada Therapeutics Inc Logo
Entrada Therapeutics Inc
NASDAQ:TRDA
Watchlist
Price: 15.1 USD 0.73%
Updated: May 20, 2024

Entrada Therapeutics Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Entrada Therapeutics Inc
Total Receivables Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Entrada Therapeutics Inc
NASDAQ:TRDA
Total Receivables
$5.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Receivables
$11.9B
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$4.7B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
4%
Amgen Inc
NASDAQ:AMGN
Total Receivables
$6.8B
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$1.8B
CAGR 3-Years
22%
CAGR 5-Years
33%
CAGR 10-Years
40%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$5.2B
CAGR 3-Years
8%
CAGR 5-Years
18%
CAGR 10-Years
17%

See Also

What is Entrada Therapeutics Inc's Total Receivables?
Total Receivables
5.9m USD

Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Total Receivables amounts to 5.9m USD.